Loading...

ABBV ABBVIE INC Disposals and divestitures 8-K Filing

BBV

BBV

ABBVIE INC

(ABBV)

2025 8-K

Debt Offering Completion

Debt Offering Announcement

Financial Results Announced

Earnings Guidance Update

Financial Results Release

Earnings Guidance Update

Litigation Settlement

Financial Statements

Earnings Releases

Financial Statements

Earnings Guidance

Senior Notes Offering

Leadership Change

Credit Agreement

Financial Results

Impairment Charge

Earnings Guidance

Management Change

Q3 Financial Results

Earnings Guidance

By-law Amendment

Earnings Reports

Earnings Guidance

Appointment of CEO

Earnings Reports

Earnings Guidance

Underwriting Agreement for ...

Management Change

Acquisition of ImmunoGen, Inc.

Financial Results Announcement

Earnings Guidance

Acquisition Agreement

Acquisition Agreement

Financial Results Announcement

Board Expansion and New Dir...

Earnings Guidance

Earnings Reports

Appointment of Officer

Earnings Reports

Earnings Guidance

Credit Agreement Amendment

Financial Results Announcement

Investor Presentation

Earnings Guidance

External Links:

AbbVie will record a non-cash impairment charge of about $3.5 billion for the emraclidine intangible asset due to disappointing trial results for schizophrenia treatment, which did not meet primary endpoints.

AI Assistant

ABBVIE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.